Bayer Investor News | Bayer Global

Stay informed about key developments at our company as they happen. Discover our Ad-Hoc Releases and subscribe to our newsletter to receive the latest news and topics of interest.

1 - 10of 418 News

1 - 10of 418 News

May 22, 2025

Not intended for U.S. and UK Media

Eylea™ 8 mg approved in China for wet age-related macular degeneration

May 13, 2025

First-quarter performance:

Bayer confirms 2025 targets after solid start to the year

May 09, 2025

Not intended for U.S. and UK Media

Aflibercept 8 mg to treat macular edema following retinal vein occlusion submitted for approval in Japan

April 25, 2025

CEO Bill Anderson at the Annual Stockholders’ Meeting:

“We’re working at full force to put Bayer back on a profitable growth path”

April 08, 2025

Not intended for U.S. and UK Media

Bayer files for approval of aflibercept 8 mg for treatment of retinal vein occlusion in EU

April 04, 2025

Bayer announces filing of petition to U.S. Supreme Court for review of Durnell Roundup™ case

March 26, 2025

Not intended for U.S. and UK Media

Bayer and Puhe BioPharma enter into global license agreement for clinical phase I PRMT5 inhibitor

March 17, 2025

Not intended for U.S. and UK Media

U.S. FDA grants Priority Review for new indication of finerenone for patients with common form of heart failure

March 05, 2025

Financial News Conference:

Bayer meets adjusted guidance and takes decisive action to tackle challenges

February 19, 2025

Not intended for UK Media

AskBio Receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease investigational gene therapy

Inform Yourself on Special Topics

Control Weeds Not Farming

Control Weeds, Not Farming

Farmers discussing their weed management

Everything You Need to Know About Glyphosate

some-bayer-group-headquarters

Managing Glyphosate Litigation

woman harvesting carrots

Managing and Mitigating PCB Litigation Risk